Bone Cancer Drugs Market
Description
Bone Cancer Drugs Market, By Drug Type ( Antimetabolites, Anthracyclines, Antibiotics, and Others (RANK ligand inhibitors, etc.)), By Disease Indication (Multiple Myeloma, Osteosarcoma, Chondrosarcoma, and Ewing’s Sarcoma), By Distribution Channel, Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
The term "bone cancer" refers to a variety of malignancies that in the bones. Normal bone tissues may suffer damage, if the cancer cells spread into a bone. The type of bone cancer depends on the cell and tissue types where the disease first manifests itself. Primary bone malignancies are tumors that originate inside the bone itself. Many cancers that start in the body organs or other tissues can spread to the bones in addition to other body parts. These growths are referred to as metastatic or secondary bone malignancies. Most tumors that metastasis (spread) to the bones are from the breast, prostate, and lung. In bone cancer, abnormal cells in bone grow out of control and destroys the normal bone tissue. It can start in bone or spread to other parts of body (called metastasis). Bone cancer is rare. Most bone tumors are benign, and thus, these are not cancerous and will not spread to other areas of your body. However, these can weaken bones and lead to fractures or other problems. There are a few common types of benign bone tumors: Osteochondroma is the most common. It is common in people under the age of 20. A giant cell tumor is present in leg. In rare cases, these can also be cancerous. Osteoid osteomas often occur in long bones, usually in the early 20s. Osteoblastoma is a rare tumor that grows in the spine and long bones, and occurs primarily in young adults. Enchondromas usually appear in the bones of hands and feet. Often there are no symptoms. It is the most common type of hand tumor. Thus, increasing prevalence of bone cancer is expected to drive growth of the global bone cancer drugs market over the forecast period.Market Dynamics
Increasing products and approvals by government regulatory bodies is expected to drive growth of the global bone cancer drugs market over the forecast period. For instance, in February 2021, the U.S. Food and Drug Administration (FDA) granted rare pediatric disease designation to the bone-targeting radiopharmaceutical samarium-153-DOTMP (CycloSam) for use as a potential therapeutic option for patients with osteosarcoma. The nuclear technology uses low specific activity samarium-153 thatreduces europium contamination, and DOTMP, a chelator designed to prevent off-target migration and at target sites with high bone turnover.
Key features of the study:
- This report provides an in-depth analysis of the global bone cancer drugs market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bone cancer drugs market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group, Merck & Co., Bayer AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical, F. Hoffmann-La Roche Ltd and Teva Pharmaceutical
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global bone cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bone cancer drugs market
- Global Bone Cancer Drugs Market, By Drug Type:
- Antimetabolites
- Anthracyclines
- Antibiotics
- Others (RANK ligand inhibitors, etc.)
- Global Bone Cancer Drugs Market, By Disease Indication:
- Multiple Myeloma
- Osteosarcoma
- Chondrosarcoma
- Ewing’s Sarcoma
- Global Bone Cancer Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Bone Cancer Drugs Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- Advaxis, Inc.
- Cellectar Biosciences, Inc.
- OPKO Health, Inc.
- Pfizer Inc.
- Amgen Inc.
- Novartis AG
- Eli Lilly and Company
- Debiopharm Group
- Merck & Co
- Bayer AG
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical
- F. Hoffmann-La Roche Ltd
- Teva Pharmaceutical
Table of Contents
204 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
